Skip to main content
Signal8
Schneiderman Daniel H profile photo

Daniel H. Schneiderman

CIK: 0001565536

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Pasithea Therapeutics Corp. logo
KTTA

Pasithea Therapeutics Corp.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Pasithea Therapeutics Corp. logo
    KTTA

    Pasithea Therapeutics Corp.

    May 1, 2026
    Award(A)

    Stock Option (right to buy)

    Direct
    1.1M shares-
  • Pasithea Therapeutics Corp. logo
    KTTA

    Pasithea Therapeutics Corp.

    Nov 28, 2025
    Award(A)
    Direct
    26.7K shares at avg. $0.75$20K
  • Pasithea Therapeutics Corp. logo
    KTTA

    Pasithea Therapeutics Corp.

    Oct 24, 2025
    Award(A)

    Stock Option (right to buy)

    Direct
    317.3K shares-

1-3 of 3

About Schneiderman Daniel H

Schneiderman Daniel H (SEC CIK 0001565536) files insider reports with the SEC as Chief Financial Officer of Pasithea Therapeutics Corp. (KTTA).

Signal8 holds 3 ownership filings by Schneiderman Daniel H, all Form 4s, filed between Oct 27, 2025 and May 5, 2026. Those filings report 3 transactions, from Oct 24, 2025 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schneiderman Daniel H's filings is in MIAMI BEACH, FL.

Recent filings by Schneiderman Daniel H

  • May 1, 2026: Grant or award of KTTA derivative securities (Form 4, code A).
  • Nov 28, 2025: Grant or award of KTTA shares (Form 4, code A).
  • Oct 24, 2025: Grant or award of KTTA derivative securities (Form 4, code A).

Other insiders filing for Pasithea Therapeutics Corp. (KTTA)

How to read Form 4 transaction codes